Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 14Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Hepatocellular 4Triple Negative Breast Neoplasms 3Sarcoma, Ewing 3Ovarian Neoplasms 3Melanoma 3Kidney Neoplasms 3Pancreatic Neoplasms 2Osteosarcoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2HIV Infections 2Endometrial Neoplasms 2Carcinoma, Medullary 2Breast Neoplasms 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

veliparib 1pamiparib 1dinaciclib 1cabozantinib 1Pharmacogenomic Variants 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Malignant Solid Neoplasm × cabozantinib × Clear all
NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡